Vaccines and compositions against
View Patent ↗Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromized patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae . The antigens may be used therapeutically or prophylactically.
1. A vaccine formulation comprising:
a pharmaceutically acceptable carrier;
an effective amount of an adjuvant;
a first isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 265, 266, or 268, or comprising the amino acid sequence of SEQ ID NO:265, 266, or 268 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a second isolated polypeptide comprising the amino acid sequence of SEQ ID NO:9 or 10, or comprising the amino acid sequence of SEQ ID NO:9 or 10 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.
2. The vaccine formulation of claim 1 , further comprising a third isolated polypeptide comprising the amino acid sequence of SEQ ID NO:6 or 7, or comprising the amino acid sequence of SEQ ID NO:6 or 7 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.
3. The vaccine formulation of claim 2 , wherein the third polypeptide consists of the amino acid sequence of SEQ ID NO:6.
4. The vaccine formulation of claim 2 , wherein the third polypeptide consists of the amino acid sequence of SEQ ID NO:7.
5. A vaccine formulation comprising:
a pharmaceutically acceptable carrier;
an effective amount of an adjuvant;
a first isolated polypeptide comprising the amino acid sequence of SEQ ID NO:265, 266, or 268, or comprising the amino acid sequence of SEQ ID NO:265, 266, or 268 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a second isolated polypeptide comprising the amino acid sequence of SEQ ID NO:6 or 7, or comprising the amino acid sequence of SEQ ID NO:6 or 7 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.
6. The vaccine formulation of claim 1 or 5 , wherein the first polypeptide consists of the amino acid sequence of SEQ ID NO:265.
7. The vaccine formulation of claim 1 or 5 , wherein the first polypeptide consists of the amino acid sequence of SEQ ID NO:266.
8. The vaccine formulation of claim 1 or 5 , wherein the first polypeptide consists of the amino acid sequence of SEQ ID NO:268.
9. The vaccine formulation of claim 1 , wherein the second polypeptide consists of the amino acid sequence of SEQ ID NO:9.
10. The vaccine formulation of claim 1 or 5 , wherein one or more polypeptides are conjugated to an immunogenic carrier.
11. The vaccine formulation of claim 1 or 5 , which comprises at least one lipidated polypeptide.
12. The vaccine formulation of claim 5 , wherein the second polypeptide consists of the amino acid sequence of SEQ ID NO:6.
13. The vaccine formulation of claim 5 , wherein the second polypeptide consists of the amino acid sequence of SEQ ID NO:7.
14. A vaccine formulation comprising:
a pharmaceutically acceptable carrier;
an effective amount of an adjuvant;
a first isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 265, 266, or 268 or comprising the amino acid sequence of SEQ ID NO:265, 266, or 268 lacking 1-3 amino acids from the N-terminus, C-terminus, or both;
a second isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 6 or comprising the amino acid sequence of SEQ ID NO:6 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a third isolated polypeptide comprising the amino acid sequence of SEQ ID NO:7 or comprising the amino acid sequence of SEQ ID NO:7 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.
15. The vaccine formulation of claim 14 , wherein the second polypeptide is lipidated.
16. The vaccine formulation of claim 14 or 15 , further comprising one or both of:
a fourth isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 9 or comprising the amino acid sequence of SEQ ID NO: 9 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a fifth isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or comprising the amino acid sequence of SEQ ID NO: 10 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.
17. The vaccine formulation of claim 16 , wherein the fifth polypeptide is lipidated.
18. A vaccine formulation comprising:
a pharmaceutically acceptable carrier;
an effective amount of an adjuvant;
a first isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 265, 266, or 268 or comprising the amino acid sequence of SEQ ID NO: 265, 266, or 268 lacking 1-3 amino acids from the N-terminus, C-terminus, or both;
a second isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 9 or comprising the amino acid sequence of SEQ ID NO: 9 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a third isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or comprising the amino acid sequence of SEQ ID NO: 10 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.
19. The vaccine formulation of claim 18 , wherein the third polypeptide is lipidated.
20. A vaccine formulation comprising:
a pharmaceutically acceptable carrier;
an effective amount of an adjuvant;
a first isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 265 or comprising the amino acid sequence of SEQ ID NO:265 lacking 1-3 amino acids from the N-terminus, C-terminus, or both;
a second isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 6 or comprising the amino acid sequence of SEQ ID NO:6 lacking 1-3 amino acids from the N-terminus, C-terminus, or both;
a third isolated polypeptide comprising the amino acid sequence of SEQ ID NO:7 or comprising the amino acid sequence of SEQ ID NO:7 lacking 1-3 amino acids from the N-terminus, C-terminus, or both;
a fourth isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 9 or comprising the amino acid sequence of SEQ ID NO: 9 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a fifth isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 10 or comprising the amino acid sequence of SEQ ID NO: 10 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.
21. The vaccine formulation of claim 20 , wherein the adjuvant is alum.
22. The vaccine formulation of claim 20 , wherein the vaccine formulation comprises 1-1000 μg of each polypeptide.
23. The vaccine formulation of any one of claim 1 , 5 , 14 , 18 , or 20 , wherein upon administration to a subject, the vaccine formulation induces an immune response against S. pneumoniae.
24. A pharmaceutical composition comprising:
a pharmaceutically acceptable carrier;
an effective amount of an adjuvant;
a first isolated polypeptide comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:265, 266, or 268, or comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:265, 266, or 268 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a second isolated polypeptide comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:9 or 10, or comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:9 or 10 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.
25. The pharmaceutical composition of claim 24 , further comprising a third isolated polypeptide comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:6 or 7, or comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:6 or 7 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.
26. A pharmaceutical composition comprising:
a pharmaceutically acceptable carrier;
an effective amount of an adjuvant;
a first isolated polypeptide comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:265, 266, or 268, or comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:265, 266, or 268 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a second isolated polypeptide comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:6 or 7, or comprising an amino acid sequence at least 98% identical to the amino acid sequence of SEQ ID NO:6 or 7 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.
27. The pharmaceutical composition of 90 or 92, wherein upon administration to a subject, the pharmaceutical composition induces an immune response against S. pneumoniae.
28. A pharmaceutical composition comprising:
a pharmaceutically acceptable carrier;
an effective amount of an adjuvant;
a first polypeptide comprising an amino acid sequence from a strain of S. pneumoniae that corresponds to the amino acid sequence of SEQ ID NO: 265, 266, or 268, or to the amino acid sequence of SEQ ID NO:265, 266, or 268 lacking 1-3 amino acids from the N-terminus, C-terminus, or both; and
a second polypeptide comprising an amino acid sequence from a strain of S. pneumoniae that corresponds to the amino acid sequence of SEQ ID NO:9 or 10, or to the amino acid sequence of SEQ ID NO:9 or 10 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.
29. The pharmaceutical composition of claim 28 , further comprising a third polypeptide comprising an amino acid sequence from a strain of S. pneumoniae that corresponds to the amino acid sequence of SEQ ID NO:6 or 7, or to the amino acid sequence of SEQ ID NO:6 or 7 lacking 1-3 amino acids from the N-terminus, C-terminus, or both.